SCHEMBL21778221

SCHEMBL21778221

C#CCOC1C[C@H](n2ccc(N)nc2=O)O[C@@H]1CO

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
PDE3A Q14432 3/20 0.50
CACNA1F O60840 2/20 0.50
ALB P02768 2/20 0.50
MAPT P10636 2/20 0.50
CACNA1D Q01668 2/20 0.50
CACNA1S Q13698 2/20 0.50
CACNA1C Q13936 2/20 0.50
THRB P10828 1/20 0.49
MTOR P42345 1/20 0.49
MDM2 Q00987 1/20 0.49
NCOA1 Q15788 1/20 0.49
NCOA3 Q9Y6Q9 1/20 0.49
KDM4E B2RXH2 1/20 0.47
POLB P06746 2/20 0.47
PDE4D Q08499 1/20 0.47
SLC29A1 Q99808 1/20 0.47
DNMT1 P26358 2/20 0.43
ADRB1 P08588 1/20 0.43
POLG P54098 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16489129 1.00 LMNA (0.50) LMNAPDE3ACACNA1FALBMAPT
SCHEMBL4579454 0.85 LMNA (0.56) LMNAPDE3ACACNA1FALBMAPT
SCHEMBL4579459 0.85 LMNA (0.56) LMNAPDE3ACACNA1FALBMAPT
SCHEMBL21778225 0.84 POLB (0.43) LMNAPDE3ACACNA1FALBMAPT
SCHEMBL16489130 0.84 POLB (0.43) LMNAPDE3ACACNA1FALBMAPT
SCHEMBL10432426 0.84 LMNA (0.55) LMNAPDE3ACACNA1FALBMAPT
SCHEMBL22300660 0.84 LMNA (0.55) LMNAPDE3ACACNA1FALBMAPT
SCHEMBL16359951 0.84 LMNA (0.55) LMNAPDE3ACACNA1FALBMAPT
SCHEMBL10431788 0.84 LMNA (0.55) LMNAPDE3ACACNA1FALBMAPT
SCHEMBL19033324 0.84 LMNA (0.55) LMNAPDE3ACACNA1FALBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210207192-A1 NUCLEOTIDE ANALOGS ABBOTT MOLECULAR INC. 2021-07-08 US disclosed
US-10577646-B2 Nucleotide analogs ABBOTT MOLECULAR INC. (US) 2020-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10577646-B2 Nucleotide analogs NUDT1, NT5C3B, RNGTT LMNA 575/4885PDE3A 889/4885CACNA1F 4592/4885
US-20210207192-A1 NUCLEOTIDE ANALOGS NUDT1, NT5C3B, RNGTT LMNA 575/4885PDE3A 889/4885CACNA1F 4592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.